Skip to main content
. 2021 Sep 20;7(10):e765. doi: 10.1097/TXD.0000000000001221

TABLE 6.

Adverse events for patients randomized to Tac and CyA-ME

Adverse event Tac (n = 40), n (%) CyA-ME (n = 74), n (%)
Tremors 10 (12.7) 13 (16.9)
Convulsions 6 (7.6) 6 (7.8)
Hypertrichosis 8 (10.1) 27 (35.0)
Gum hyperplasia 6 (7.8) 20 (30.0)
Bone disease 8 (10.1) 8 (10.4)
Diabetes 1 (1.3) 0 (0.0)
HOCM 1 (1.3) 0 (0.0)

CyA-ME, cyclosporine A microemulsion; HOCM, hypertrophic cardiomyopathy; Tac, tacrolimus.